NYULH Metastasis Research Network Center (NYULH MetNet Center)

NYULH 转移研究网络中心(NYULH MetNet 中心)

基本信息

  • 批准号:
    10705068
  • 负责人:
  • 金额:
    $ 165.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-15 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

OVERALL SUMMARY Conventional views of cancer as a predominantly genetic disease that proceeds in a step-wise, linear manner, have ceded to an understanding that tumor progression involves a multifaceted set of tumor cell-intrinsic and micro-environmental adaptations that co-evolve dynamically and non-linearly. However, much remains to be discovered about how different cell populations in the local environment drive metastatic behavior at different stages of tumor progression. Primary melanomas that are only millimeters thick can disseminate to lymph nodes and distant organs. This clinical feature suggests that egress of tumor cells from a primary site occurs early in melanoma development making melanoma an exceptional model to study these dynamic adaptations during the earliest stages of tumor progression. Our central hypothesis is that melanoma metastasis is driven by a combination of tumor cell–intrinsic features and interactions with micro-environmental compartments that govern early dissemination and immune evasion in the regional draining lymph nodes. To test this hypothesis, we propose three inter-related projects, supported by three cores that will collectively build an in- depth transcriptional and cellular map of critical compartments in the tumor microenvironment during early melanoma dissemination, in both mouse models and patient biospecimens. Successful completion of these projects will identify genes and transcriptional programs within those compartments that drive and maintain tumorigenic adaptations and ultimately metastatic dissemination. Our aims are to: 1. Map the cellular and molecular evolution of primary melanomas and their local and regional microenvironments to identify critical ‘switches’ that drive non-linear tumor progression; 2. Mechanistically dissect the emergence and functional relevance of transcriptionally defined cell state heterogeneity of malignant and non-malignant cell populations; 3. Identify novel therapeutic vulnerabilities to intercept early dissemination, mobilize systemic immune surveillance, and improve patient outcomes; and 4. Leverage the information gained to define new biomarkers of melanoma metastasis. We expect that knowledge generated through our approach may define new biomarkers of melanoma metastasis and therapeutic strategies to manage early disease. Our approach can serve as a roadmap to study early tumor progression at an unprecedented level of cellular, spatial and temporal resolution. It will provide a comprehensive picture of interactions both within the tumor microenvironment and tumor draining lymph nodes that influence tumor cell behavior and condition the host to be receptive to metastatic spread. We will leverage the complementary and synergistic expertise of our research team with an established record of productive collaboration, our novel genetically engineered mouse model that recapitulates early progression of human melanoma, and our access to high quality, clinically annotated patient samples from over 4,700 patients enrolled in a prospective clinicopathological database. The scope and scalability of the knowledge gained will serve other sites of the Metastasis Research Network.
整体总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eva Hernando其他文献

Eva Hernando的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eva Hernando', 18)}}的其他基金

Developing new therapeutic strategies for brain metastasis
开发脑转移的新治疗策略
  • 批准号:
    10578405
  • 财政年份:
    2023
  • 资助金额:
    $ 165.45万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10414443
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
NYULH Metastasis Research Network Center - Admin Supplement
NYULH 转移研究网络中心 - 管理补充
  • 批准号:
    10867093
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
Project 1: Tumor Cell Intrinsic Determinants of Early Dissemination in Melanoma
项目1:黑色素瘤早期播散的肿瘤细胞内在决定因素
  • 批准号:
    10705072
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10902230
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
NYULH Metastasis Research Network Center (NYULH MetNet Center)
NYULH 转移研究网络中心(NYULH MetNet 中心)
  • 批准号:
    10414442
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
Project 1: Tumor Cell Intrinsic Determinants of Early Dissemination in Melanoma
项目1:黑色素瘤早期播散的肿瘤细胞内在决定因素
  • 批准号:
    10414444
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
Defining epigenetic regulators of tumor heterogeneity and metastasis in melanoma
定义黑色素瘤肿瘤异质性和转移的表观遗传调节因子
  • 批准号:
    10659255
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
Defining epigenetic regulators of tumor heterogeneity and metastasis in melanoma
定义黑色素瘤肿瘤异质性和转移的表观遗传调节因子
  • 批准号:
    10512423
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10705069
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:

相似国自然基金

分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    56 万元
  • 项目类别:
    面上项目
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 批准年份:
    2020
  • 资助金额:
    53 万元
  • 项目类别:
    面上项目
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
  • 批准号:
    81903002
  • 批准年份:
    2019
  • 资助金额:
    20.5 万元
  • 项目类别:
    青年科学基金项目
HA/CD44在乳腺癌转移“先导细胞”(leader cells)侵袭中的作用及机制研究
  • 批准号:
    81402419
  • 批准年份:
    2014
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
  • 批准号:
    81271563
  • 批准年份:
    2012
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
  • 批准号:
    31272541
  • 批准年份:
    2012
  • 资助金额:
    82.0 万元
  • 项目类别:
    面上项目
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
  • 批准号:
    31271248
  • 批准年份:
    2012
  • 资助金额:
    80.0 万元
  • 项目类别:
    面上项目
无外源性基因iPS cells向肠细胞分化及对肠损伤的修复
  • 批准号:
    81160050
  • 批准年份:
    2011
  • 资助金额:
    49.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Search for damage-associated molecular patterns (DAMPs) derived from cochlear hair cells and its clinical application
耳蜗毛细胞损伤相关分子模式(DAMPs)的探索及其临床应用
  • 批准号:
    23K08924
  • 财政年份:
    2023
  • 资助金额:
    $ 165.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Comprehensive basic research for the development of therapies targeting senescent cells and their clinical applications
针对衰老细胞的疗法开发及其临床应用的综合基础研究
  • 批准号:
    23H05487
  • 财政年份:
    2023
  • 资助金额:
    $ 165.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (S)
PFI-TT: Development of artificial substrates for growth of human stem cells suitable for clinical applications
PFI-TT:开发适合临床应用的人类干细胞生长人工基质
  • 批准号:
    2234541
  • 财政年份:
    2023
  • 资助金额:
    $ 165.45万
  • 项目类别:
    Standard Grant
Elucidation of the molecular mechanism of activated B cells in the pathogenesis of hypersensitivity pneumonitis and its clinical significance.
阐明活化B细胞在过敏性肺炎发病中的分子机制及其临床意义。
  • 批准号:
    23K07622
  • 财政年份:
    2023
  • 资助金额:
    $ 165.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research and development for clinical practical application by analysis of circulation tumor cells of hepatobiliary-pancreatic cancer
肝胆胰癌循环肿瘤细胞分析及临床应用研究进展
  • 批准号:
    23K14662
  • 财政年份:
    2023
  • 资助金额:
    $ 165.45万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Full-scale GMP Production for a Pre-Clinical Systemic Delivered Mesenchymal Stem Cells Derived Extracellular Vesicles For Cardiovascular Disease
用于治疗心血管疾病的临床前全身输送间充质干细胞衍生的细胞外囊泡的全面 GMP 生产
  • 批准号:
    10721103
  • 财政年份:
    2023
  • 资助金额:
    $ 165.45万
  • 项目类别:
Rapid, single-step precision engineering and pre-clinical evaluation of chimeric antigen receptor Regulatory T cells for Type 1 diabetes
嵌合抗原受体调节性 T 细胞治疗 1 型糖尿病的快速、单步精密工程和临床前评估
  • 批准号:
    10477106
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
Development of detection system for oral cancer patient's blood circulating tumor cells and prediction of clinical pathology and prognosis using it
口腔癌患者血液循环肿瘤细胞检测系统的开发及临床病理及预后预测
  • 批准号:
    22K10146
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
Ultra-high speed AO-OCT clinical system to image ganglion cells and microglia
超高速 AO-OCT 临床系统对神经节细胞和小胶质细胞进行成像
  • 批准号:
    10547181
  • 财政年份:
    2022
  • 资助金额:
    $ 165.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了